TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: COPM performance scores post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noradrenaline spillover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulsativity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echogenic pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participant-rated disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: BBS sum score reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6m walking test reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ever having wheezed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: allergic rhinitis ever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in serum IGF‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Symptom frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premature ventricular complex (PVC) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: treatment adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevated levels of IGF‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Elevated levels of P‐III‐NP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in RQLQ score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived healthcare and support needs met
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in sE-selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma MDA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxidative resistance of LDL (lag-time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased familiar discretionary snack food consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative energy balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in wrist, hand, and/or finger discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ counts or percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: p24 antigenaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clearance of PAX2‐ and PTEN‐null glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac decompensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: health care utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of pockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reported discomfort/pain
Endpoint domain: Adverse events/effects
Primary endpoint: mean total travelling time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: hospitalizations for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angina frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical limitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: therapeutic cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median time-to-resolution of fishy odor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of symptom return
Endpoint domain: Adverse events/effects
Primary endpoint: 12-month depression severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radial tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nerve injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Complete clearance of all treated AK lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean daily pain relief score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of daily doses of study medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean number of daily doses of supplemental analgesics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Grade 4 late bladder complications
Endpoint domain: Adverse events/effects
Primary endpoint: Acute bowel toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: re-admission rates
Endpoint domain: Mortality/survival
Primary endpoint: Physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: major neurological recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of a positive screening for depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of diabetes medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closed angle detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement with gonioscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACD measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association between TST and anti-LAM test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Provocation dose for allergens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of salicylic acid absorbed in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Erythrocyte membrane stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HgCl2-depressed osmolality (Ohyper)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte AQP1 protein content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of strokes
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in hemorrhagic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Postoperative functional scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postdilutional hematocrit decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Magnesium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clot formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Auditory and visual order thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: free PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hyponatraemia at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial nerve preservation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percent body fat change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARAT (Action Research Arm Test) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active motor threshold for hand muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRQoL improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 6MW test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eating disorder symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in SHS exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of liver enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in liver synthetic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic fibrosis assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient confidence in symptom management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: tolerance time during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-perceived cognitive abilities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: use of memory strategies
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Controlled Verbal Learning Test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient satisfaction regarding ability to chew
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fugl‐Meyer upper extremity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper extremity movement subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall acceptability of using smartphones
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Color alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Survival at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Pelvic relapse rates
Endpoint domain: Adverse events/effects
Primary endpoint: Child asthma self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: median survival times
Endpoint domain: Mortality/survival
Primary endpoint: overall response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain relief rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eligibility for the study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tone identification improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major cardiac adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: C(max) and AUC of fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usage of assistive devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance of knee bracing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: More than mild PAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvements in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Inhibition of plaque regrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Cholinesterase activity in blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Combined permeability score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central endothelial cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resting systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Back pain
Endpoint domain: Adverse events/effects
Primary endpoint: surgical time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incision length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: volume of blood losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ratio of pulmonary and systemic vascular resistance (Rp:Rs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality following surgery
Endpoint domain: Mortality/survival
Primary endpoint: Development of right heart failure secondary to pulmonary hypertension
Endpoint domain: Adverse events/effects
Primary endpoint: Technical success rate for spermatic vein occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of varicocele
Endpoint domain: Adverse events/effects
Primary endpoint: PASI75 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in total SHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite blepharitis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraocular pressure (IOP) increases
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Cor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: component costs
Endpoint domain: Resource use
Primary endpoint: treatment times
Endpoint domain: Resource use
Primary endpoint: Percentage of protected sex acts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy for condom use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean IOP measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness against irritants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Knee symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in primary and secondary outcome measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage who self-rated their progress as a major improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative platelet counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reinfarction rate
Endpoint domain: Mortality/survival
Primary endpoint: Mortality at 1 year after PCI
Endpoint domain: Mortality/survival
Primary endpoint: Maximum insulin concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum glucose response (R(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin sensitivity (G(tot)/AUC(0‐t'))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: missed radiographic findings
Endpoint domain: Adverse events/effects
Primary endpoint: waiting time in the ED
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: HIV or HSV-2 infection rates
Endpoint domain: Mortality/survival
Primary endpoint: treatment uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FAAM-ADL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PJA (Pelvic Joint Angle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PJK (Pelvic Joint Kink)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in physical component summary of SF-36
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PCa-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Minimum Lumen Area (MLA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eosinophil count in nasal smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nasal airway resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Catheter-associated bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Local catheter infection
Endpoint domain: Adverse events/effects
Primary endpoint: Overall late complication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of AST, ALT and Lac
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Duration of stay at the ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of participants no longer meeting criteria for PTSD
Endpoint domain: Mortality/survival
Primary endpoint: maximal work rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of angiogenic gene therapy using NV1FGF
Endpoint domain: Adverse events/effects
Primary endpoint: intrusive memories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: explicit memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aldosterone to Renin Ratio (ARR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency of major deviations
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of minor deviations
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Uric Acid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of elevated low density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean LDL-C reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mF-G scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hormone levels (luteinising hormone, total testosterone, free testosterone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Duration of Org 9426-induced neuromuscular blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in Larsen score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percentage of new joint involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percentage of damaged joint progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean serum 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in PC20 FEV1 from baseline averaged over the 7-day observation period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of uncovered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of malapposed struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of major arrhythmias
Endpoint domain: Adverse events/effects
Primary endpoint: marked improvement to complete clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic infections prevention
Endpoint domain: Adverse events/effects
Primary endpoint: Ductus arteriosus treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes